Oncology – Lung
Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations.
3 Jun, 2022 | 11:02h | UTCRelated:
Preoperative exercise training for patients with non‐small cell lung cancer – Cochrane Library
Cardiac metastasis from solid cancers: a 35-year single-center autopsy study.
3 Jun, 2022 | 10:54h | UTC
M-A: Stereotactic radiosurgery vs. whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer.
30 May, 2022 | 10:41h | UTCStereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)
Single-arm, phase II trial: overall survival and biomarker analysis of neoadjuvant Nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer.
30 May, 2022 | 10:39h | UTC
Commentary on Twitter
In NADIM study of neoadj chemo + nivo for stage IIIA NSCLC, 3-y OS was 91%; low levels of pretreatment ctDNA and undetectable ctDNA after neoadjuvant therapy were predictive of OS (with HRs of 0.07 and 0.04, respectively) https://t.co/BIprSnDICd
— NatureRevClinOncol (@NatRevClinOncol) May 18, 2022
RCT: Tiragolumab plus atezolizumab vs. placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer.
27 May, 2022 | 11:11h | UTCTiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: First-line tiragolumab–atezolizumab promising for PD-L1-positive advanced NSCLC – Medicine Matters
RCT: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer.
27 May, 2022 | 11:09h | UTCAdebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
RCT: Aumolertinib vs. Gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations.
26 May, 2022 | 10:10h | UTC
Commentary on Twitter
Aumolertinib (a 3rd gen TKI) is effective in the first-line treatment of EGFR-mutant NSCLC-AENEAShttps://t.co/QL6xXptxFa pic.twitter.com/grIbapsxzU
— K Pavithran (@drkpavithran) May 18, 2022
https://creativecommons.org/licenses/by-nc-nd/4.0/
Update on image-guided thermal lung ablation: Society guidelines, therapeutic alternatives, and postablation imaging findings.
4 May, 2022 | 08:14h | UTC
RCT: Segmentectomy resulted in better outcomes than lobectomy in small-sized peripheral non-small-cell lung cancer.
25 Apr, 2022 | 01:03h | UTCSegmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
RCT: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.
12 Apr, 2022 | 08:54h | UTCNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer – New England Journal of Medicine
News Release: Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients with Lung Cancer – Johns Hopkins Medicine
Commentary on Twitter
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemo results in longer event-free survival and a greater likelihood of pathological complete response than chemo alone. #AACR22 https://t.co/ILjdRZQ7dJ pic.twitter.com/1JfiUw18R6
— NEJM (@NEJM) April 11, 2022
Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study.
31 Mar, 2022 | 08:23h | UTCEditorial: Screening high risk populations for lung cancer
News Release: US lung cancer screening linked to earlier diagnosis and better survival – British Medical Journal
Related:
Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.
Commentary on Twitter
Increases in the early detection of lung cancer since 2014 in the US have saved an estimated 10,100 lives, but screening rates are still extremely low and disparities in access to lung cancer screening continue to exist, say researchers https://t.co/j58LfcGCKU
— The BMJ (@bmj_latest) March 31, 2022
Multicenter comparative accuracy trial: Dynamic contrast-enhanced CT vs. positron emission tomography CT to characterize solitary pulmonary nodules.
16 Mar, 2022 | 08:51h | UTCDownload: Full Report
Review: Current surgical indications for non-small-cell lung cancer.
11 Mar, 2022 | 08:39h | UTCCurrent Surgical Indications for Non-Small-Cell Lung Cancer – Cancers
RCT: Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions.
8 Mar, 2022 | 08:28h | UTCRole of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Thoracic ultrasonography-guided pleurodesis in patients with malignant pleural effusions results in shorter hospital stay without reducing the success rate of the procedure at 3 monthshttps://t.co/hof4Rd2nUt
— K Pavithran (@drkpavithran) March 2, 2022
RCT: In patients with early-stage lung cancer, video-assisted thoracoscopic lobectomy is associated with better recovery of physical function at 5 weeks.
3 Mar, 2022 | 08:42h | UTCVideo-Assisted Thoracoscopic or Open Lobectomy in Early-Stage Lung Cancer – NEJM Evidence
Commentary on Twitter
For patients with early-stage #LungCancer, resection by video-assisted thoracoscopic surgery was superior to open resection with respect to postoperative recovery of physical function as shown in a randomized trial. @ekslim @RBandH #VATS #OncoAlert https://t.co/j23CgZp5U5 pic.twitter.com/UsIx3D8Zem
— NEJM Evidence (@NEJMEvidence) January 19, 2022
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumors.
3 Mar, 2022 | 08:08h | UTC
ASCO Guideline Update: Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non–small-cell lung cancer.
23 Feb, 2022 | 10:08h | UTC
Commentary on Twitter
‼️ Just published in #JCO: @ASCO rapid guideline update on adjuvant systemic therapy & adjuvant radiation therapy for stage I to IIIA completely resected #NSCLC 🫁 https://t.co/OheQi7Bi97 #lcsm #radonc pic.twitter.com/Dax2orUXZy
— Journal of Clinical Oncology (@JCO_ASCO) February 15, 2022
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
7 Feb, 2022 | 08:36h | UTC
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer.
4 Feb, 2022 | 08:38h | UTCOriginal Study: Randomized Trial: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
RCT: Sugemalimab improves progression-free survival vs. placebo in patients with metastatic non-small-cell lung cancer.
1 Feb, 2022 | 08:25h | UTCSugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial – The Lancet Oncology (link to abstract – $ for full-text)
Related study: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Sugemalimab shows promise for locally advanced, metastatic NSCLC – Medicine Matters
Sugemalimab Boosts Outcomes in NSCLC – MedPage Today (free registration required)
Commentary on Twitter
https://twitter.com/NatRevClinOncol/status/1483839169839255554
Systematic Review: Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent.
27 Jan, 2022 | 09:15h | UTC
ASCO Guideline: Management of stage III non–small-cell lung cancer.
18 Jan, 2022 | 09:12h | UTCManagement of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline – Journal of Clinical Oncology
RCT: Postoperative radiotherapy (PORT) did not increase disease-free survival compared with no PORT in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement.
8 Jan, 2022 | 22:38h | UTCPostoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Post-Operative Radiotherapy Not Tied to Better Disease-Free Survival in NSCLC – MedPage Today (free registration required)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
8 Dec, 2021 | 09:47h | UTC
Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.
28 Nov, 2021 | 21:22h | UTCExecutive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report
Full Guideline: Screening for Lung Cancer: CHEST Guideline and Expert Panel Report
News Release: CHEST releases expert guidelines for lung cancer screening – Elsevier
Related:
Commentary on Twitter
CHEST Guidelines and Expert Panel Report contains 16 evidence-based recommendations for the benefits, harms, and implementation of low-dose chest computed tomography (CT) screening. https://t.co/4mvjEOftQl #CHESTOnc #CHESTGuidelines #LungCancerAwarenessMonth pic.twitter.com/uyh9Pf0s5s
— CHEST® Journal (@journal_CHEST) November 23, 2021